Checkpoint inhibitors, for example, have been developed to target and block the immune checkpoint proteins CTLA-4, PD-1, and PD-L1, which are upregulated in tumor and immune cells and restrict the immune system from attacking the tumor. Here, CD274 is linked to neoplasm.